News | December 13, 2011

MBI Proven to be Equivalent to MRI in the Detection of Breast Cancer

December 13, 2011Molecular breast imaging (MBI) has been found to be equivalent to magnetic resonance imaging (MRI) as an adjunct imaging modality in the diagnosis of breast cancer. MBI may be especially useful for the evaluation of high-risk women or those with dense breasts.

According to the study authors, MRI has become increasingly popular as an adjunct to mammography in the diagnosis of breast cancer. Despite its sensitivity in lesion detection, MRI is expensive and can cause patient discomfort. MBI has similar sensitivity to MRI, costs less and is comfortable for the patient. This study aimed to directly compare the two modalities.

It was concluded that MBI results led to further workup and detection of occult malignancies. In fact, negative MRIs without contradictory MBI results would have led to six missed malignant tumors in this study. Also, the authors noted that as the study demonstrated MBI’s equivalency to MRI in the diagnosis of breast cancer, that MBI may be useful for the evaluation of high-risk women or those with dense breasts. For this study MBI was conducted with a high-resolution gamma camera, the Dilon 6800.

Beyond demonstrating that MBI is equivalent to MRI in the diagnoses of breast cancer, Nathalie Johnson, M.D., chief breast surgeon at Legacy Good Samaritan Hospital in Portland, Ore., and author on this study, said, “Its application may be particularly relevant for evaluation of newly diagnosed breast cancer to rule out additional disease with a lower false positive rate.” Additional researchers on the study were Esther Han, M.D. and Margie Glissmeyer in Portland, Ore.

As a follow-up to mammography, MBI utilizes the Dilon 6800 gamma camera to help physicians more clearly differentiate benign from malignant tissue. To perform MBI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal healthy cells and generally appear as dark spots on the MBI image.

For more information: www.dilon.com

Related Content

Study Examines Characteristics of Mobile Mammography Patients
News | Mammography | October 18, 2017
Significant differences were found among women receiving mammography at a cancer center versus those visiting a mobile...
Machine Learning Identifies Breast Lesions Likely to Become Cancer
News | Artificial Intelligence | October 18, 2017
A machine learning tool can help identify which high-risk breast lesions are likely to become cancerous, according to a...
Volpara Solutions to Showcase VolparaEnterprise Live! at RSNA
News | Mammography | October 16, 2017
Volpara Solutions will introduce VolparaEnterprise Live!, a mammography quality control tool, at the 2016 Radiological...
TMIST Mammography Study Opens Enrollment
News | Mammography | October 16, 2017
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare two types of...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
Joint Venture Partnership Opening 16 New Breast Screening Sites in Texas
News | Breast Imaging | October 04, 2017
HCA Healthcare Gulf Coast Division and Solis Mammography have entered into a joint venture agreement to make breast...
Kubtec Announces Expansion of 3-D Tomosynthesis Technology
News | Digital Radiography (DR) | October 04, 2017
October 4, 2017 — Kubtec announced at the annual conference of the American Association of Pathology Assistants (AAPA
The Siemens Acuson

The Siemens Acuson

Feature | Breast Imaging | October 04, 2017 | By Melinda Taschetta-Millane
According to a new Market Study Report,1 the automated breast ultrasound system (ABUS) market will see a 21 percent...
Hologic’s new Brevera breast biopsy system allows real-time tissue sample collection and verification on one system

Hologic’s new Brevera breast biopsy system allows real-time tissue sample collection and verification on one system.

Feature | Breast Imaging | October 03, 2017 | By Jeff Zagoudis
When it comes to breast imaging, mammography has long been the gold standard among breast cancer detection technologies...
Hologic rings Nasdaq bell for breast cancer awareness
News | Breast Imaging | October 02, 2017
Hologic Inc. announced that Steve MacMillan, the company's chairman, president and CEO, joined selected employees to...
Overlay Init